Atlas Trials

Essential Thrombocythemia (ET)

14 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Essential Thrombocythemia (ET)

RecordFirmDate
Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms (NCT06798805)IRCCS Azienda Ospedaliero-Universitaria di Bologna2022-02-15
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients (NCT04243122)Ottawa Hospital Research Institute2021-02-17
National Longitudinal Cohort of Hematological Diseases (NCT04645199)Institute of Hematology & Blood Diseases Hospital, China2020-12-01
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia (NCT02577926)RWTH Aachen University2015-10-01
Agrylin Drug Use-Result Survey (NCT03625895)Takeda2014-11-25
Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms (NCT01816256)University Health Network, Toronto2013-05-01
Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID® (NCT01352585)Shire2011-07-19
Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia (NCT01467661)Shire2010-10-27
Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia (NCT01214915)Shire2010-10-27
Pediatric Disease Registry in Essential Thrombocythaemia (ET) (NCT01198717)Shire2010-09-28

Track Essential Thrombocythemia (ET) automatically

Every clearance here is in the API, with alerts when new ones post.